Valuation: PolyPeptide Group AG

Market Cap 1.56B 1.74B 1.44B 1.31B 2.45B 165B 2.48B 17.3B 6.87B 86.71B 6.54B 6.4B 275B P/E 2026 *
58.3x
P/E 2027 * 30.9x
Enterprise Value 1.66B 1.85B 1.54B 1.39B 2.6B 176B 2.64B 18.42B 7.32B 92.31B 6.96B 6.81B 293B EV / Sales 2026 *
3.32x
EV / Sales 2027 * 2.94x
Free-Float
39.12%
Yield 2026 *
-
Yield 2027 * 0.14%
1 day+0.11%
1 week-0.34%
Current month-0.11%
1 month-0.11%
1 week 43.8
Extreme 43.8
44.05
1 month 43
Extreme 43
44.15
Current year 43
Extreme 43
44.15
1 year 43
Extreme 43
44.15
3 years 43
Extreme 43
44.15
5 years 43
Extreme 43
44.15
10 years 43
Extreme 43
44.15
Manager TitleAgeSince
Chief Executive Officer 54 12/04/2023
Director of Finance/CFO 54 02/01/2024
Chief Tech/Sci/R&D Officer 54 -
Director TitleAgeSince
Director/Board Member 73 01/01/2006
Chairman 69 01/04/2021
Director/Board Member 62 01/01/2021
Change 5-day change 1-year change 3-year change Capi.($)
+0.11%-0.34% - - 1.75B
-0.13%-0.36%+54.77%+128.30% 1,140B
+0.75%+3.63%+41.24%+84.60% 641B
-0.10%-0.88%+25.65%+106.24% 507B
+0.63%+2.33%+49.21%+67.82% 383B
+0.89%-4.34%+61.20%+37.97% 347B
+1.02%+1.80%+24.84%+53.75% 293B
-0.25%+1.62%+2.20%+26.65% 266B
+0.48%+1.76%+53.41%+70.77% 240B
-0.46%+0.82%+30.98%+105.94% 197B
Average +0.24%+2.92%+38.17%+75.78% 445.98B
Weighted average by Cap. +0.22%+2.98%+42.04%+88.24%

Financials

2026 *2027 *
Net sales 502M 559M 463M 420M 785M 53.12B 795M 5.56B 2.21B 27.84B 2.1B 2.05B 88.29B 576M 642M 532M 482M 901M 60.96B 913M 6.38B 2.53B 31.95B 2.41B 2.36B 101B
Net income 23.5M 26.19M 21.7M 19.68M 36.78M 2.49B 37.24M 260M 103M 1.3B 98.31M 96.2M 4.13B 45.23M 50.39M 41.76M 37.87M 70.78M 4.79B 71.65M 501M 199M 2.51B 189M 185M 7.96B
Net Debt 101M 112M 93.22M 84.53M 158M 10.68B 160M 1.12B 444M 5.6B 422M 413M 17.76B 131M 146M 121M 110M 205M 13.85B 207M 1.45B 576M 7.26B 547M 536M 23.03B
Projected Income Statement - Annual - PolyPeptide Group AG
Logo PolyPeptide Group AG
Polypeptide Group AG is a Switzerland-based Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.
Employees
1,460
Date Price Change Volume
28/10/26 CHF 43.95 +0.11% 17,240
26/10/26 CHF 43.90 0.00% 5,815
23/10/26 CHF 43.90 0.00% 28,423
22/10/26 CHF 43.90 -0.23% 16,643
21/10/26 CHF 44.00 -0.23% 37,770
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - PolyPeptide Group AG
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
47.34EUR
Average target price
45.99EUR
Spread / Average Target
-2.87%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - PolyPeptide Group AG